28697-11-2Relevant articles and documents
Synthesis method of 3-hydroxy-2-piperidinecarboxylic acid compound and synthesis method of hydrochloride thereof
-
Paragraph 0091-0094, (2021/05/29)
The invention discloses a synthesis method of 3-hydroxy-2-piperidinecarboxylic acid compound and a synthesis method of hydrochloride thereof. According to the invention, (S)-piperidine-2-formic acid is used as an initial raw material, (2S)-N-(quinoline-8-
Pipecolic esters as minimized templates for proteasome inhibition
Giletto, Matthew B.,Osmulski, Pawel A.,Jones, Corey L.,Gaczynska, Maria E.,Tepe, Jetze J.
, p. 2734 - 2746 (2019/03/12)
Allosteric regulators of clinically important enzymes are gaining popularity as alternatives to competitive inhibitors. This is also the case for the proteasome, a major intracellular protease and a target of anti-cancer drugs. All clinically used proteasome inhibitors bind to the active sites in catalytic chamber and display a competitive mechanism. Unfortunately, inevitable resistance associated with this type of inhibition drives the search for non-competitive agents. The multisubunit and multicatalytic “proteolytic machine” such as the proteasome is occasionally found to be affected by agents with other primary targets. For example the immunosuppressive agent rapamycin has been shown to allosterically inhibit the proteasome albeit at levels far higher than its mTOR related efficacy. As part of an ongoing program to search for novel proteasome-targeting pharmacophores, we identified the binding domain of rapamycin as required for proteasome inhibition even without the macrocyclic context of the parent compound. By subsequent structure-activity relationship studies, we generated a pipecolic ester derivative compound 3 representing a new class of proteasome inhibitors. Compound 3 affects the core proteasome activities and proliferation of cancer cells with low micromolar/high nanomolar efficacy. Molecular modeling, atomic force microscopy imaging and biochemical data suggest that compound 3 binds into one of intersubunit pockets in the proteasomal α ring and destabilizes the α face and the gate. The α face is used as a docking area for proteasome-regulating protein modules and the gate is critical for controlling access to the catalytic chamber. Thus, the pipecolic ester template elicits a new and attractive mechanism for proteasome inhibition distinct from classical competitive drugs.
Cis-fused ring-containing β-lactam the synthetic method of the compound of
-
Page/Page column 3, (2016/12/01)
The invention discloses a synthetic method of a beta-lactam compound with a cis condensed ring. Substituted or un-substituted pyrrole-2-formic acid, or substituted or un-substituted pyridine-2-formic acid or substituted or un-substituted indole-2-formic acid is used as a starting material, Pd(II) is adopted as a catalyst, and AgOAc or Ag2CO3 is used as an oxidant; a sp3C-H bond at a beta site of an amide substrate 2 (for example Scheme4) is activated through palladium catalysis; a key step of forming a C-N bond in a molecule to successfully construct a beta-lactam framework with the cis condensed ring is generated. According to the synthetic method disclosed by the invention, materials are simple and easily available, the price is cheap, the experiment operation is simple, the route is short and the yield is high; the synthetic method has very high atom economy, a little waste, environment friendliness, a wide scope of application of the substrate and good universality, and can be used for efficiently obtaining the beta-lactam compound with optical activity kept in a chiral manner.
